Show simple item record

Radiofrequency fields, transthyretin, and Alzheimer's disease.

dc.contributor.authorSöderqvist, Fredrik
dc.contributor.authorHardell, Lennart
dc.contributor.authorCarlberg, Michael
dc.contributor.authorMild, Kjell Hansson
dc.date.accessioned2020-02-06T16:38:12Z
dc.date.available2020-02-06T16:38:12Z
dc.date.issued2010-05-27
dc.identifier.urihttp://dx.doi.org/10.3233/JAD-2010-1395
dc.identifier.urihttps://lib.digitalsquare.io/xmlui/handle/123456789/3659
dc.description.abstractRadiofrequency field RF exposure provided cognitive benefits in an animal study In Alzheimer s disease AD mice exposure reduced brain amyloid beta Abeta deposition through decreased aggregation of Abeta and increase in soluble Abeta levels Based on our studies on humans on RF from wireless phones we propose that transthyretin TTR might explain the findings In a cross sectional study on 313 subjects we used serum TTR as a marker of cerebrospinal fluid TTR We found a statistically significantly positive beta coefficient for TTR for time since first use of mobile phones and desktop cordless phones combined P 0 03 The electromagnetic field parameters were similar for the phone types In a provocation study on 41 persons exposed for 30 min to an 890 MHz GSM signal with specific absorption rate of 1 0 Watt kg to the temporal area of the brain we found statistically significantly increased serum TTR 60 min after exposure In our cross sectional study use of oral snuff also yielded statistically significantly increased serum TTR concentrations and nicotine has been associated with decreased risk for AD and to upregulate the TTR gene in choroid plexus but not in the liver another source of serum TTR TTR sequesters Abeta thereby preventing the formation of Abeta plaques in the brain Studies have shown that patients with AD have lowered TTR concentrations in the cerebrospinal fluid and have attributed the onset of AD to insufficient sequestering of Abeta by TTR We propose that TTR might be involved in the findings of RF exposure benefit in AD mice
dc.relation.uriJournal of Alzheimer's disease : JAD
dc.titleRadiofrequency fields, transthyretin, and Alzheimer's disease.en
dcterms.abstractRadiofrequency field RF exposure provided cognitive benefits in an animal study In Alzheimer s disease AD mice exposure reduced brain amyloid beta Abeta deposition through decreased aggregation of Abeta and increase in soluble Abeta levels Based on our studies on humans on RF from wireless phones we propose that transthyretin TTR might explain the findings In a cross sectional study on 313 subjects we used serum TTR as a marker of cerebrospinal fluid TTR We found a statistically significantly positive beta coefficient for TTR for time since first use of mobile phones and desktop cordless phones combined P 0 03 The electromagnetic field parameters were similar for the phone types In a provocation study on 41 persons exposed for 30 min to an 890 MHz GSM signal with specific absorption rate of 1 0 Watt kg to the temporal area of the brain we found statistically significantly increased serum TTR 60 min after exposure In our cross sectional study use of oral snuff also yielded statistically significantly increased serum TTR concentrations and nicotine has been associated with decreased risk for AD and to upregulate the TTR gene in choroid plexus but not in the liver another source of serum TTR TTR sequesters Abeta thereby preventing the formation of Abeta plaques in the brain Studies have shown that patients with AD have lowered TTR concentrations in the cerebrospinal fluid and have attributed the onset of AD to insufficient sequestering of Abeta by TTR We propose that TTR might be involved in the findings of RF exposure benefit in AD mice
dcterms.contributorSöderqvist, Fredrik
dcterms.contributorHardell, Lennart
dcterms.contributorCarlberg, Michael
dcterms.contributorMild, Kjell Hansson
dcterms.identifierhttp://dx.doi.org/10.3233/JAD-2010-1395
dcterms.relationJournal of Alzheimer's disease : JAD
dcterms.titleRadiofrequency fields, transthyretin, and Alzheimer's disease.en


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • mhealth Evidence [20971]
    mHealth Evidence was launched in 2012 to bring together the world’s literature on “mHealth” (broadly speaking, the application of mobile technologies to health service delivery).

Show simple item record

Digital Square is a PATH-led initiative funded and designed by the United States Agency for International Development, the Bill & Melinda Gates Foundation, and a consortium of other donors.

Funders' Logos

This platform is made possible by the generous support of the American people through the United States Agency for International Development (USAID). The contents of this platform are the sole responsibility the respective course developers as noted within the platform, and do not necessarily reflect the views of PATH, USAID, the United States Government, or PATH’s funders.